LAUSR

587Background: Conditional survival (CS) indicates the probability that patient would survive additional periods, given that the patients has previous survivorship after diagnosis or initial treatment. Here, we aim to evaluate the CS probabilities in mRCC patients who underwent targeted therapy with tyrosine kinase inhibitors (TKI) and to identify the significant prognostic factors of the CS over time. Methods: A total of 1,498 mRCC patients receiving 1st line TKI was finally analyzed from Korean multicenter database of mRCC. Kaplan-Meier survival estimates was used to calculate overall and cancer-specific CS rates by using following formula: CS(α│β) = S(α+β)/S(β), where CS(α│β) indicates the likelihood of additional α years survivorship in the person who has already survived for β years after initial diagnosis or treatment, and S(χ) is the actual survival rate. The Cox regression analysis was used to determine the predictors of CS depended on clinicopathological features. Results: We observed that 1, 2, ...